Precision BioSciences (DTIL) to Release Earnings on Wednesday

Precision BioSciences (NASDAQ:DTIL) is anticipated to release its earnings data before the market opens on Wednesday, March 26th. Analysts expect Precision BioSciences to post earnings of ($2.09) per share and revenue of $4.28 million for the quarter.

Precision BioSciences Stock Performance

Shares of NASDAQ:DTIL opened at $5.64 on Tuesday. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. The company has a 50-day moving average price of $5.14 and a 200-day moving average price of $6.66. The company has a market cap of $43.26 million, a price-to-earnings ratio of 94.02 and a beta of 1.59. Precision BioSciences has a 12 month low of $3.61 and a 12 month high of $15.97.

Insider Buying and Selling

In other Precision BioSciences news, CEO Michael Amoroso sold 36,838 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $4.67, for a total transaction of $172,033.46. Following the completion of the transaction, the chief executive officer now owns 107,087 shares of the company’s stock, valued at approximately $500,096.29. This trade represents a 25.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider J. Jefferson Smith sold 10,287 shares of the business’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $4.79, for a total transaction of $49,274.73. Following the sale, the insider now owns 87,440 shares in the company, valued at approximately $418,837.60. This trade represents a 10.53 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders purchased 8,734 shares of company stock valued at $39,946 and sold 47,279 shares valued at $222,064. 4.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

DTIL has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a report on Wednesday, March 19th. BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target for the company in a research note on Friday, January 10th.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.